The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021

Wallace, Megan; Woodworth, Kate R.; Gargano, Julia W.; Scobie, Heather M.; Blain, Amy; Moulia, Danielle; Chamberland, Mary E.; Reisman, Nicole; Hadler, Stephen C.; MacNeil, Jessica R.; Campos‐Outcalt, Doug; Morgan, Rebecca L.; Daley, Matthew F.; Romero, José R.; Talbot, H. Keipp; Lee, Grace M.; Bell, Beth P.; Oliver, Sara E.

doi:10.15585/mmwr.mm7020e1

Cited by 138 publications

(104 citation statements)

References 2 publications

Supporting

Mentioning

103

Contrasting

Order By: Relevance

“…The potential risks of vaccines against COVID-19 remain unknown for adult-onset SLE patients and the optimal dose for efficacy may be different from that in healthy subjects, however, the risks of not receiving the immunization are far greater currently [119]. Preliminary data for one COVID-19 immunization (messenger RNA vaccine) in a placebo-controlled trial of 2200 adolescents aged 12-15 years showed 100% efficacy and a strong immune response [120]. This may be relevant to efforts to control the pandemic, since this group of patients may have a role in viral transmission [121] and a distinct phenotype from adults with less symptomatic disease [122].…”

Section: General Treatmentmentioning

confidence: 99%

An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus

et al. 2021

View full text Add to dashboard Cite

Childhood-onset systemic lupus erythematosus (cSLE) is a prototype of a multisystemic, inflammatory, heterogeneous autoimmune condition. This disease is characterized by simultaneous or sequential organ and system involvement, with unpredictable flare and high levels of morbidity and mortality. Racial/ethnic background, socioeconomic status, cost of medications, difficulty accessing health care, and poor adherence seem to impact lupus outcomes and treatment response. In this article, the management of cSLE patients is updated. Regarding pathogenesis, a number of potential targets for drugs have been studied. However, most treatments in pediatric patients are off-label drugs with recommendations based on inadequately powered studies, therapeutic consensus guidelines, or case series. Management practices for cSLE patients include evaluations of disease activity and cumulative damage scores, routine non-live vaccinations, physical activity, and addressing mental health issues. Antimalarials and glucocorticoids are still the most common drugs used to treat cSLE, and hydroxychloroquine is recommended for nearly all cSLE patients. Disease-modifying antirheumatic drugs (DMARDs) should be standardized for each patient, based on disease flare and cSLE severity. Mycophenolate mofetil or intravenous cyclophosphamide is suggested as induction therapy for lupus nephritis classes III and IV. Calcineurin inhibitors (cyclosporine, tacrolimus, voclosporin) appear to be another good option for cSLE patients with lupus nephritis. Regarding B-cell-targeting biologic agents, rituximab may be used for refractory lupus nephritis patients in combination with another DMARD, and belimumab was recently approved by the US Food and Drug Administration for cSLE treatment in children aged > 5 years. New therapies targeting CD20, such as atacicept and telitacicept, seem to be promising drugs for SLE patients. Anti-interferon therapies (sifalimumab and anifrolumab) have shown beneficial results in phase II randomized control trials in adult SLE patients, as have some Janus kinase inhibitors, and these could be alternative treatments for pediatric patients with severe interferon-mediated inflammatory disease in the future. In addition, strict control of proteinuria and blood pressure is required in cSLE, especially with angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use.

show abstract

Section: General Treatmentmentioning

confidence: 99%

An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The European Medicine Agency (EMA) approved Comirnaty in people from 16 years of age on 21 December 2020. On 10 May 2021, the FDA expanded EUA to use the Pfizer mRNA COVID-19 vaccine for children 12–15 years [ 4 ]. The Center for Disease Control and Prevention (CDC) subsequently recommended on 12 May 2021, that persons 12 years and older should get a COVID-19 vaccine.…”

Section: Introductionmentioning

confidence: 99%

Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?

et al. 2021

View full text Add to dashboard Cite

This is a cross-sectional study of 29 published cases of acute myopericarditis following COVID-19 mRNA vaccination. The most common presentation was chest pain within 1–5 days after the second dose of mRNA COVID-19 vaccination. All patients had an elevated troponin. Cardiac magnetic resonance imaging revealed late gadolinium enhancement consistent with myocarditis in 69% of cases. All patients recovered clinically rapidly within 1–3 weeks. Most patients were treated with non-steroidal anti-inflammatory drugs for symptomatic relief, and 4 received intravenous immune globulin and corticosteroids. We speculate a possible causal relationship between vaccine administration and myocarditis. The data from our analysis confirms that all myocarditis and pericarditis cases are mild and resolve within a few days to few weeks. The bottom line is that the risk of cardiac complications among children and adults due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection far exceeds the minimal and rare risks of vaccination-related transient myocardial or pericardial inflammation.

show abstract

“…The smoothed 3-week running average rate of COVID-19-associated hospitalizations during the week ending January 9, 2021 (displayed in Figure2) is 1.3 hospitalizations per 100,000 children and adolescents. ¶ ¶ ¶ ¶ Among the3,194 children and adolescents with COVID-19-associated hospitalizations during March 1, 2020-June 19, 2021, a total of 3,116 (97.6%) had data available on hospital length of stay, ICU admission, receipt of IMV or other respiratory support, vasopressor use, and inhospital death at the time of reporting.…”

mentioning

confidence: 99%

Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021

Delahoy¹,

Ujamaa²,

Whitaker³

et al. 2021

MMWR Morb. Mortal. Wkly. Rep.

Self Cite

261

206

View full text Add to dashboard Cite

this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr).Although COVID-19-associated hospitalizations and deaths have occurred more frequently in adults, † COVID-19 can also lead to severe outcomes in children and adolescents (1,2). Schools are opening for in-person learning, and many prekindergarten children are returning to early care and education programs during a time when the number of COVID-19 cases caused by the highly transmissible B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, is increasing. § Therefore, it is important to monitor indicators of severe COVID-19 among children and adolescents. This analysis uses Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET) ¶ data to describe COVID-19-associated hospitalizations among U.S. children and adolescents aged 0-17 years. During March 1, 2020-August 14, 2021, the cumulative incidence of COVID-19-associated hospitalizations was 49.7 per 100,000 children and adolescents. The weekly COVID-19-associated hospitalization rate per 100,000 children and adolescents during the week ending August 14, 2021 (1.4) was nearly five times the rate during the week ending June 26, 2021 (0.3); among children aged 0-4 years, the weekly hospitalization rate during the week ending August 14, 2021, was nearly 10 times that during the week ending June 26, 2021.** During June 20-July 31, 2021, the hospitalization rate among unvaccinated adolescents (aged 12-17 years) was 10.1 times higher than that among fully vaccinated adolescents. Among all hospitalized children and adolescents with COVID-19, the proportions * These authors contributed equally to this report.

show abstract

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021

Cited by 138 publications

References 2 publications

An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus

An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus

Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?

Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021

Contact Info

Product

Resources

About